Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications
Moneer O, Mooghali M, Moosa K, Ramachandran R, Ross J, Dhruva S. Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications. Health Affairs 2024, 43: 1712-1718. PMID: 39626147, DOI: 10.1377/hlthaff.2024.00182.Peer-Reviewed Original ResearchConceptsCentury Cures ActLocal coverage determinationsCures ActQuality of evidenceHigh-risk devicesCoverage decisionsPatient ageClinical evidenceClinical studiesCoverage determinationMedical literatureTherapeutic drugsSixty-fiveCoverage databaseEvidence strengthEvidence qualityEvidence summaryActMedicare coverage decisionsMedicare beneficiary populationPremarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies
Mooghali M, Wallach J, Ross J, Ramachandran R. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies. JAMA Network Open 2024, 7: e2430486. PMID: 39190303, PMCID: PMC11350476, DOI: 10.1001/jamanetworkopen.2024.30486.Peer-Reviewed Original ResearchConceptsFood and Drug Administration tableFood and Drug AdministrationSurrogate end pointsSurrogate markerPostmarketing studiesEnd pointsTraditional approvalCross-sectional studyClinical benefitAccelerated approvalTherapy designClinically significant end pointsReview of therapeuticsPrimary end pointUS Food and Drug AdministrationTrial end pointsSignificant end pointsPostmarketing requirementsPreliminary clinical evidenceApproval pathwayPivotal trialsClinical evidenceBreakthrough therapiesDrug AdministrationTherapy